Thus, KL-6 could be a reliable biomarker to assess SSc-ILD severity; however, further studies are necessary to confirm its utility for diagnosis, prognosis, and prediction of therapeutic responsiveness. This evidence concerns the gene MUC1 and interstitial lung disease.